Table 1

Studies evaluating the relation between apolipoprotein E genotype and cognitive response to acetylcholinesterase inhibitor therapy for Alzheimer’s disease

Study	Sample	Design	Predictor evaluated	Drug(s)	Responder definition	Results
Poirier et al31	n = 40	30-wk double-blind clinical trial	ApoE4 genotype	Tacrine	ADAS-cog scores at 30 wk	Advantage: ApoE4 negative
Farlow et al33	n = 528, mild-tomoderate AD	30-wk double-blind placebo-controlled	ApoE genotype, sex	Tacrine	ADAS-cog at 30 wk	Advantage: ApoE2–3 women only
MacGowan et al34	n = 68 tacrine 3 mo n = 32 tacrine extension n = 39 galantamine	Tacrine: 3-mo double-blind trial and open-label extension (up to 12 mo) Galantamine: 3-mo open-label trial	ApoE4 genotype, sex	Tacrine, galantamine	MMSE at end of treatment	Advantage: men, 3 mo only No advantage: ApoE4 carriers, 12 mo
Farlow et al35	n = 959, mild-tomoderate AD	Pooled from 4 prospective, randomized, double-blind, placebo-controlled trials	ApoE4 genotype, sex	Metrifonate	ADAS-cog at wk 12 or 26 CIBIC-Plus at wk 12 or 26	No significant differences ApoE genotype or sex
Rigaud et al36	n = 76, mild-to-moderate AD (33 E4+, 43 E4−)	Open-label study, 6 wk on each dose (40, 80, 120, 160 mg/d)	ApoE4 genotype, sex	Tacrine	4-point decrease on ADAScog at each dosage increment	No significant differences ApoE genotype or sex
Wilcock et al27	n = 653, mild-tomoderate AD	6 mo double-blind parallel group placebo-controlled trial	ApoE4 genotype	Galantamine	ADAS-cog at 3, 6 mo	No significant effect of ApoE genotype
Oddoze et al37	n = 84	Open-label study, 6-mo treatment	ApoE4 genotype	Donepezil	MMSE after 6 mo of treatment	Advantage: ApoE4 carriers
Aerssens et al38	n = 1528, mild-tomoderate AD	Pooled from 4 double-blind placebocontrolled trials, 3–12 mo	ApoE4 genotype	Galantamine	ADAS-cog score after treatment	No significant effect of ApoE genotype
Almkvist et al39	n = 24, mild AD	Double-blind randomized placebocontrolled trial of single dose administration	ApoE4 genotype	Tacrine	Measures of attention	Advantage: ApoE4 carriers
Winblad et al40	n = 286, mild to moderate AD	Double-blind randomized placebocontrolled multicentre trial	ApoE4 genotype, sex	Donepezil	Gottfries-Bråne-Steen at 6, 9 and 12 mo	No significant differences ApoE genotype or sex

Note: ApoE = apolipoprotein E; ADAS-cog = Alzheimer’s Disease Assessment Scale-cognitive subscale; AD = Alzheimer’s disease; MMSE = Mini-Mental Status Examination; CIBIC-Plus = Clinician’s Interview-Based Impression of Change with Caregiver Input.